SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing heightened volatility as the CME implements multiple margin requirement hikes, fueling intense community debate over market manipulation. Many perceive these actions as a concerted effort to suppress prices and liquidate leveraged positions, especially with reported disparities between paper and physical silver values globally. Despite calls of a "rigged game" and comparisons to past crashes, a strong bullish contingent anticipates a significant long-term rally driven by robust industrial demand and ongoing concerns about supply.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to high anticipation for upcoming FDA decisions regarding AXS-05 for Alzheimer's agitation and AXS-12 for narcolepsy, with the community optimistic about potential approvals. This regulatory excitement is complemented by strong, consistent prescription growth and expanding market access for its major depressive disorder treatment, Auvelity. Investors are keenly focused on these catalysts and the company's broader CNS pipeline, despite some impatience with communication around timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Barfresh Food Group (NASDAQ:BRFH) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Barfresh Food Group (NASDAQ:BRFH) Shares Cross Above 200-Day Moving Average - What's Next...

Vita Coco Company, Inc. (COCO) Q3 Earnings and Revenues Beat Estimates

Vita Coco Company (COCO) delivered earnings and revenue surprises of +25.00% and +14.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Keurig Dr Pepper, Inc (KDP) Meets Q3 Earnings Estimates

Keurig Dr Pepper (KDP) delivered earnings and revenue surprises of 0.00% and +4.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Barfresh Food Group Inc. (BRFH) Reports Q2 Loss, Misses Revenue Estimates

Barfresh Food Group (BRFH) delivered earnings and revenue surprises of 0.00% and -31.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Barfresh Food Group (BRFH) rose 5.12% in after-hours trading on Wednesday ahead of the frozen beverage maker’s fourth-quarter earnings, but retail sentiment stayed downbeat.Wall Street analysts expect the company to post a 14.6% rise in revenue in Q4 to $4.17 million. The company is expected to post a loss per share of $0.01 in Q4. The company has beaten revenue estimates twice in the past three quarters.In February, Barfresh reportedly secured a $3 million strategic financing round for common stock at $2.85 per share, supported by its existing shareholders.The funding was aimed at the expansion of its manufacturing capabilities to meet growing customer demand in its education channel and its new Pop &amp; Go 100% Juice Freeze Pops, which showed promising results in select testing.In the third quarter, Barfresh Food Group reported a loss per share of $0.03 , missing estimates of loss per share of $0.01 but its revenue of $3.64 million beat estimates of $3.61 million, increasing &nbsp;40% year-on-year.In 2024, the company saw improvements in Twist &amp; Go bottled smoothie sales from inventory built ahead of its seasonally high third quarter."Our strategic investments and operational enhancements have driven exceptional results, with record quarterly third quarter revenue exceeding $3.6 million, a 40% year-over-year increase,” CEO Riccardo Delle Coste said at the time of its last earnings.The company saw revenue contribution from its new Pop &amp; Go product and some success from improved sales and distribution.Sentiment on Stocktwits was ‘extremely bearish’ on Wednesday compared to neutral a week ago. Message volume inched up in the ‘extremely low’ zone.<figure class="image"><img style="aspect-ratio:1332/332;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_11_33_45_AM_png_62ea471548.webp" alt="Screenshot 2025-03-27 at 11.33.45 AM.png" width="1332" height="332"><figcaption>BRFH sentiment meter and message volume on March 26</figcaption></figure>Barfresh stock is up 12.3% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo by Christoph Soeder/picture alliance via Getty Images)

Barfresh Stock Rises After-Hours Ahead Of Earnings: Retail's Downbeat

 In the third quarter, Barfresh reported a loss per share of $0.03

Equity

Barfresh Food Group, Inc. engages in the development, manufacture, and distribution of ready to blend frozen beverages. Its portfolio of products comprises smoothies, shakes, and frappes. The company was founded by Riccardo Delle Coste on February 25, 2010 and is headquartered in Los Angeles, CA.

BRFH
Barfresh Food Group Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BRFH News

BRFHBarfresh Food Group Inc